AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Sex Differences in Statin Intensity and Low Density Lipoprotein Cholesterol Goal Attainment After Percutaneous Coronary Intervention
By Sajjan S, Carrion Isaacs E, Procopi N et al.
Introduction: Statin is a cornerstone of secondary prevention after percutaneous coronary intervention (PCI) to lower low density liproprotein cholesterol (LDL-C). Prior studies suggest women are less likely to receive high-intensity statin (HIS) therapy and achieve LDL-C targets after coronary revascularization. Research Question: In a large contemporary cohort, are there sex differences in statin intensity and LDL-C target attainment after PCI? Methods: We included consecutive patients undergoing PCI at a large US tertiary center between January 2012 and December 2023 with baseline and ≥1 follow-up LDL-C measurement obtained ≥21 days post-PCI. Patients with cardiac arrest, cardiogenic shock, active malignancy or dialysis were excluded. LDL-C <70 mg/dL was used as the primary threshold, consistent with the 2018 ACC/AHA Blood Cholesterol. Statin therapy at discharge was classified as HIS, low/moderate statin, or no statin. The co-primary endpoints were: (1) the proportion of patients achieving LDL-C <70 mg/dL at baseline, stratified by sex; and (2) among those with unattained LDL-C target at baseline (≥70 mg/dL), the proportion reaching LDL-C <70 mg/dL within one year, stratified by sex and statin intensity at discharge. Results: Among 9,260 patients (2,573 women [27.8%], mean age 69.4±11.5 vs. 65.8±11.5 years in men), baseline LDL-C≥70mg/dL was more prevalent in women than men (65.3% vs. 54.3%, p<0.001), despite women carrying a higher burden of CV risk factors. Statin was prescribed in 99.2% overall at discharge, similarly in women and men. HIS at discharge did not differ significantly between sexes (58.1% vs. 60.8%, p=0.142). Among patients with unattained LDL-C target at baseline, goal attainment within 1 year was significantly lower in women than men (33% vs. 46%), and this gap persisted across all statin intensity groups (HIS: 22% vs. 30%; moderate/low statin: 11% vs. 15%; both p<0.001) ( Figure 1 ). This sex gap in LDL-C levels was stable over 18 months ( Figure 2 ). Conclusions: Women undergoing PCI had a higher prevalence of LDL-C ≥70 mg/dL at baseline than men despite greater CV risk burden. Despite similar statin intensity at discharge, the sex-based difference in LDL-C observed at baseline persisted over 18 months of follow-up, suggesting that statin therapy alone did not close this gap.